secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0000950170-24-117406
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma sells rights to ME-344 to Aardvark Therapeutics for up to $62.5M milestones
--------------------------------------------------------------------------------

- Closed on Oct 22, 2024: sold ME-344 assets (IP, contracts, technology) to Aardvark Therapeutics for $0.5M upfront plus $55K reimbursement.
- Potential milestone payments up to $62M tied to regulatory approval and sales milestones for ME-344.
- Purchaser assumes certain liabilities under transferred contracts; no material relationship between parties.
- Company retains all other assets and liabilities not specifically transferred (Excluded Assets and Liabilities).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024117406/0000950170-24-117406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024117406/meip-20241022.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-117406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer